Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABLIS or log reduction from the baseline level?
Authors:
- Qian JiangQJQian Jiang
- Hao JiangHJHao Jiang
- Jin-Lan LiJLJin-Lan Li
- Ling-Di LiLLLing-Di Li
- Hong-Hu ZhuHZHong-Hu Zhu
- Yue-Yun LaiYLYue-Yun Lai
- Xi-Jing LuXLXi-Jing Lu
- Yan-Rong LiuYLYan-Rong Liu
- Bin JiangBJBin Jiang
- Xiao-Jun HuangXHXiao-Jun Huang
- 1 September 2013
- journal article
- research article
- Published by Elsevier in Leukemia Research
- Vol. 37 (9) , 1035-1040
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)Leukemia, 2012
- Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase InhibitorsJournal of Clinical Oncology, 2012
- Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Blood, 2010
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate–treated patients with CMLBlood, 2006
- Achieving a Major Molecular Response at the Time of a Complete Cytogenetic Response (CCgR) Predicts a Better Duration of CCgR in Imatinib-Treated Chronic Myeloid Leukemia PatientsClinical Cancer Research, 2006
- Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Serial monitoring of BCR–ABL by peripheral blood real‐time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemiaBritish Journal of Haematology, 2002
- Monitoring chronic myeloid leukaemia therapy by real‐time quantitative PCR in blood is a reliable alternative to bone marrow cytogeneticsBritish Journal of Haematology, 1999
- Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCRLeukemia, 1999